Vareniclina

989 views

Published on

Published in: Health & Medicine
  • Be the first to comment

Vareniclina

  1. 1. VareniclinaAndrea Isabel Arteaga
  2. 2. Action at 42 nicotine receptor Partial agonist/antagonist Releases lower amounts of dopamine intobrain than smoke • Reduces withdrawal • Not as addictive as smokeBlocks nicotine from binding to receptor • Prevents reward of smoking
  3. 3. Farmacocinética Concentración Vida media 17- máxima 4h 24h Mucosa Excreción renal gástrica Vareniclina
  4. 4. Mecanismo de acción
  5. 5. Efectos adversos Sleep Nausea Constipation Disturbance changes in Vomiting Gas behavior
  6. 6. Evidencia
  7. 7. Varenicline phase 2 trial CO-confirmed 4-week continuous quit rates, at week 1260 50.650 45.140 0.5 mg 2/day30 1.0 mg 2/day Placebo20 12.410 p<0.00010
  8. 8. Varenicline clinical trial CO-confirmed 4-week continuous quit rates, at week 745 40.84035 3130 28.6 0.3 mg 1/day 25.4 1.0 mg 1/day25 1.0 mg 2/day20 13.8 Zyban 150*215 Placebo105 p<0.050
  9. 9. Varenicline 12 semaines + si succès encore 12 semaines varenicline ou placebo80 717060 5050 12 sem + placebo40 12+12 sem3020100 Communiqué de presse du 15 nov 2005, Pfizer
  10. 10. Increased CV risk with smoking cessation drug varenicline: New meta-analysis Sources1. Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated withvarenicline: a systematic review and meta-analysis. CMAJ 2011. Available at:http://www.cmaj.ca2. Hays JT. Varenicline for smoking cessation: Is it a heartbreaker? CMAJ 2011.

×